Tumours respond differently to immunotherapies compared with chemotherapeutic drugs,
raising questions about the assessment of changes in tumour burden—a mainstay of …

CNS metastases are the most common cause of malignant brain tumours in adults. Historically,
patients with brain metastases have been excluded from most clinical trials, but their …

As the applications of metabolic imaging are expanding, radiolabeled amino acids may
gain increased clinical interest. This review first describes the basic aspects of amino acid …

Background Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has
shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two …

The value of any new therapeutic strategy or treatment is determined by the magnitude of its
clinical benefit balanced against its cost. Evidence for clinical benefit from new treatment …

For accurate and reliable gene expression analysis, normalization of gene expression data
against housekeeping genes (reference or internal control genes) is required. It is known …

A M r 110,000 protein (p110) is overexpressed in P-glycoprotein-negative multidrug-resistant
tumor cell lines of different histogenetic origins. These cell lines show an ATP-dependent …

The composition of the gut microbiome has been associated with clinical responses to
immune checkpoint inhibitor (ICI) treatment, but there is limited consensus on the specific …

Classical chemotherapeutic anti-cancer treatments induce cell death through DNA damage
by taking advantage of the proliferative behaviour of cancer cells. The more recent approach …

Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of
patients with several tumor types, but predicting patient benefit using approved diagnostics is …